Payer-Pharma Perspectives on Outcomes-based Contracting

The adoption of outcomes based agreements (OBA) is growing given the urge among payers to reduce their exposure to risks of uncertain clinical value and budgetary impact, and the demand for drug manufacturers to demonstrate real world value to justify new, high-priced therapies and guarantee access to existing products exposed to increasing rebate levels. Prior to discussing practical considerations for the OBA implementation in this white paper, we’ve included the voices and rationales of two seasoned OBA pioneers and let you be party to their personal reflections.

Read More
Topics:

The Shifting Landscape for Outcomes-Based Contracting

As health systems are driven to accept increasing accountability, payers and providers are looking for the biopharmaceutical industry to share the risks around performance of their products. Outcomes-based agreements (OBA) can be seen as the next chapter of the pay-for-value trend wherein the reimbursement for the pharmaceutical product is tied to the measurable ‘real world’ value it provides in terms of predefined outcomes.

Read More
Topics:

The Six Stages to a Successful Value-Based Risk-Sharing Agreement

Outcome based agreements (OBAs) are a type of value-based risk sharing agreement between payers and drug manufacturers. OBAs are a useful tool for managing uncertainty regarding a drug’s real world clinical benefit, the economic impact to a payer’s budget, and market penetration. Read this white paper to learn about a six-stage process that will put you on the right path for attaining a successful OBA!

Read More
Topics:

Prescription Drug Pricing: “The Times They Are A-Changin”

Ulrich Neumann

“Come senators, congressmen Please heed the call Don’t stand in the doorway Don’t block up the hall For he that gets hurt Will be he who has stalled” Bob Dylan recorded his iconic “The Times They Are a Changin’” in 1963; the song was released on the 1964 album by the same name. One of […]

Read More
Topics: Evidence and Market Access

Real World Evidence Marches Forward in Drug Development

Ulrich Neumann

The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm on real-world evidence (RWE) and its adoption in the drug development process. While the collection of real-world data (RWD) and use of RWE is not new, they are now poised to have a profound impact on our industry.  Today, it […]

Read More
Topics: Evidence and Market Access